AUTONOMY BIO
LIVE

Serial Number

99046434

Owner

Autonomy Bio, Inc.

Attorney

Ranjini Acharya

Filing Date

Feb 18, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AUTONOMY BIO Trademark

Serial Number: 99046434

AUTONOMY BIO is a trademark filed by Autonomy Bio, Inc. on February 18, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Autonomy Bio, Inc.

512 2nd ST, Floor 3
San Francisco, CA 94107

Entity Type: 03

Trademark Details

Filing Date

February 18, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for anti-aging, including drugs formulated to delay or reverse age-related physiological decline; Prescription and over-the-counter medications for preventing or delaying human aging; Pharmaceutical compounds designed for reducing or reversing declines associated with aging; Therapeutic agents for improving skin and systemic health through pharmaceutical intervention; Medical preparations for increasing healthspan and lifespan.; Gene therapy products, namely, genetically engineered tissues for anti-aging purposes; Stem cells for medical purposes; Biologic tissue products, namely, genetically engineered tissues and stem cells for use in regenerative medicine; Nutraceuticals for use as a dietary supplement for delaying or reversing age-related decline; Pharmaceutical products for the personalized treatment for delaying or reversing age-related decline; Wearable drug delivery devices sold filled with pharmaceutical preparations for delaying or reversing age-related decline; Dietary supplements, protein supplements, and protein peptide supplements all containing amino acids as peptides; Dietary and nutritional supplements; Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for delaying or reversing age-related decline

Stem cell therapy services; Regenerative medicine services

Pharmaceutical research and development services focusing on anti-aging and longevity therapeutics; Drug discovery platform as a service (PaaS) featuring a computer software platform for identifying drug synergies and optimizing clinical trial protocols; Scientific research and consulting in the field of gerontology and human anti-aging.; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Stem cell research services; Providing temporary use of on-line non-downloadable cloud computing software using artificial intelligence (AI) for use in machine learning for predicting and optimizing human lifespan; Performing scientific research or providing scientific research services to identify novel biomarkers to aid in new drug development and clinical trial processes related to delaying or reversing age-related decline; Consulting services for others in the field of design, planning, and implementation project management of clinical trials for anti-aging drugs

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 8, 2026 CNSA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 20, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 20, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jan 20, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 16, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 16, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 8, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 8, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 31, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 31, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 31, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 24, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 18, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 18, 2025 NWOS
NEW APPLICATION ENTERED
Feb 18, 2025 NWAP